FDA ANTIBIOTIC REGULATION REPEAL WORKING GROUP CO-CHAIRED BY LUMPKIN, JOHNSTON; AGENCY TO MEET WITH PhRMA, GENERICS TRADE GROUPS ON PEDIATRIC EXCLUSIVITY
FDA's antibiotic regulation repeal working group is compiling a list of "old" antibiotics that will not be eligible for patent or exclusivity protection in the future, Office of Generic Drugs Deputy Director Gordon Johnston told the National Association of Pharmaceutical Manufacturers Feb. 3 in Puerto Rico.
You may also be interested in...
Innovator pharmaceutical companies will not be able to block approval of generic drugs by using the citizen petition mechanism, according to FDA's Nov. 30 proposed rule to revise the petition process.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011